Clinical trial
Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma
NCT00003356 · University of Rochester, Other · Completed
Key facts
| NCT number | NCT00003356 |
|---|---|
| Title | Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma |
| Official title | A Phase II Study of Rituxan and IL-2 in Patients With Low Grade or Follicular B-Cell Lymphoma |
| Lead sponsor | University of Rochester, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological |
| Interventions | aldesleukin, rituximab |
| Enrollment | 58 |
| Start date | Nov 1, 1997 |
| Primary completion | May 1, 2002 |
| Completion | May 1, 2002 |
| First posted | Mar 22, 2004 |
| Last update posted | Oct 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: